Startup profile · funding coverage
Kasvu Therapeutics funding, valuation and investors
TrkB-targeted neuroplastogens for brain disorders.
Keep track of Kasvu Therapeutics
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series A
€30M · September 24, 2026
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
Not publicly disclosed
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
series a · Helsinki, Finland
Investors in latest funding
Lead: Hadean Ventures
Other: Tesi , Innovestor Life Science Fund , Finnish Drug Discovery Center , Stephen Industries , Nordic Science Investments , Helsinki University Funds
Overview
Finnish biotechnology company developing TrkB-potentiating neuroplastogens for neuropsychiatric and neurodegenerative disorders.
Why Kasvu Therapeutics is interesting
Kasvu's lead program offers a differentiated attempt to enhance neuroplasticity without relying on psychedelic mechanisms, but remains preclinical.
Funding history (newest first)
Series A
2026-09-24 €30M- Hadean Ventures (lead)
- Tesi (participant)
- Innovestor Life Science Fund (participant)
- Finnish Drug Discovery Center (participant)
- Stephen Industries (participant)
- Nordic Science Investments (participant)
- Helsinki University Funds (participant)
Source: https://ddcenter.fi/fddc-joins-kasvu-therapeutics-e30-million-series-a-financing-round/
Market / IPO context
Editorial / static context — not a live quote.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.